Development of a diagnostic biomarker panel for early-stage lung adenocarcinoma using serum-derived small RNAs
Year: 2026
Type: article
Study design: Observational Study
Abstract: OBJECTIVE: Circulating small RNAs, such as microRNAs (miRNAs) and transfer RNA fragments (tRFs), reportedly reflect the physiological and pathological conditions in various diseases. Herein, we aimed to identify circulating small RNAs for the early diagnosis of lung adenocarcinoma. METHODS: This study included 40 healthy controls and 43 patients with lung adenocarcinoma. We analyzed their serum using small RNA sequencing and identified differentially expressed small RNAs between healthy controls and patients with lung adenocarcinoma. We verified the expression profiles of these small RNAs in 29 patients with lung adenocarcinoma and 27 healthy controls. Finally, we evaluated our current results by performing machine learning-based analysis. RESULTS: The expressions of two mature miRNAs (miR-193a-5p, miR-423-5p), one miRNA isoform (isomiR) (miR-423-5p(21nt)), and two tRFs (tRF-Gly(CCC)(29nt), tRF-Gly(CCC)(30nt)) were significantly elevated in patients with lung adenocarcinoma than in healthy controls. Moreover, the expressions of one miRNA (miR-20a-5p) and five tRFs (tRF-iMet(CAT)(31nt), tRF-Lys(CTT), tRF-iMet(CAT)(30nt), tRF-iMet(CAT)(29nt), tRF-Val(AAC)) were significantly decreased in patients with lung adenocarcinoma than in healthy controls (area under the curve [AUC] values = 0.71 to 0.85, respectively). Furthermore, a combination of six small RNAs (miR-193a-5p, miR-423-5p(21nt), miR-20a-5p, tRF-Gly(CCC)(29nt), tRF-iMet(CAT)(29nt), and tRF-Val(AAC)) was useful for developing a biomarker panel for the early diagnosis of lung adenocarcinoma. Discovery screening revealed that the panel demonstrated a sensitivity of 0.954 and a specificity of 0.925 (AUC = 0.974), whereas the validation data demonstrated a sensitivity of 0.690 and a specificity of 0.926 (AUC = 0.924). CONCLUSION: Serum-derived small RNAs are associated with the status of patients with lung adenocarcinoma, and evaluating small RNAs in serum is a promising non-invasive approach for diagnosing lung adenocarcinoma at an early stage.
Source: PLoS ONE
Authors: Daisuke Ueda(Data curation, Formal analysis, Investigation, Visualization, Writing – original draft), Ryou-u Takahashi(Methodology, Writing – review & editing), Yasuhiro Tsutani(Conceptualization, Formal analysis, Methodology, Supervision), Yukie Nishiyama(Methodology, Validation), Yumiko Koi(Investigation), Yuta Ibuki(Investigation), Yoshihiro Miyata(Supervision), Tomoyuki Akita(Formal analysis), Junko Tanaka(Formal analysis), Morihito Okada(Funding acquisition, Project administration, Resources, Supervision), Hidetoshi Tahara(Conceptualization, Funding acquisition, Project administration, Resources, Supervision)
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,382
OpenAlex ID: W7233870783
